NovarceEntresto's treatment of HFpEE heart failure has been approved

February 18, 2021 / Medical Information List: NovartEntresto's treatment for HFpEE heart failure was approved; all high-risk areas in the country were cleared; Sanofi injected 2.5 million euros into Novodiscovery... Daily fresh medicine news, speed reading society and you pay attention to! Part1 policy brief the national high-risk areas all zero from 0:00 on the 18th: Harbin Limin Development Zone Yutian Street adjusted to low risk, Hulan District construction road street adjusted to low risk.
In addition, there are only four medium-risk areas left in the country, namely, Shijiazhuang City, Hebei Province, Wangkui County, Yihua City, Shanghai Pudong New Area, Gaodong Town, the first phase of the new district, and Tonghua City, Jilin Province, Dongchang District, five districts.
(CCTV News) The first variant of the new coronavirus found in the United States and The United Kingdom is easy to spread and drug-resistant February 18, the world's multi-country variant of the new coronavirus, U.S. scientists found that the variant strain from the United Kingdom and the variant virus strain from California, the United States, formed a new strain, this is the first time since the outbreak found a variant of the new coronavirus complex.
scientists are not yet known about the impact of the new strain, but worry that it could lead to a new phase of the pandemic.
(Caixin) The State Drug Administration revised the six-flavored yellow preparation instructions on February 18, the State Drug Administration issued a notice that decided to six-flavored yellow preparations (including pills, capsules, tablets, adhesives, omelettes, granules) instructions "adverse reactions" (taboos) and "precautions" for a unified revision.
(National Drug Administration) Hong Kong SAR Government: Recognizing the emergency use of the New Crown Vaccine in Hong Kong on 18 February, the HKSAR Government issued a press release speaking that the Secretary for Food and Health had approved the emergency use of the New Crown Vaccine in Hong Kong in accordance with the Prevention and Control of Disease (Use of Vaccines) Regulations.
information provided by vaccine suppliers, the first batch of about 1 million doses of Kosing vaccine to be ready for Hong Kong will soon arrive in Hong Kong, according to the communique.
(Hong Kong SAR Government Press Gazette) Part2 watched Sanofi inject 2.5 million euros into Novodiscovery on February 16th, and NOVA announced that it had raised 2.5 million euros from Sanofi in its A2 round of financing.
funds will be used to advance NOVA's electronic clinical trial simulation platform, JINKO, which provides best-in-class clinical trial simulations to predict drug efficacy and optimize clinical trial development.
to run disease models in virtual patients to support decision-making and reduce clinical development risk.
(Sina Pharmaceutical News) Qiming venture capital investment enterprise Nohui Health successfully landed on the Main Board of the Hong Kong Stock Exchange Qiming Venture Capital Enterprise Nohui Health today successfully landed on the main board of the Hong Kong Stock Exchange, becoming the first stock of China's cancer early screening.
Qiming Ventures has invested in Nohui Health for four consecutive rounds since Round B, and after the IPO, Qiming Ventures has a stake of 8.59 percent.
Health's offering price of HK$26.66 per share, opening at HK$76 per share, jumped 185.07 per cent to a market capitalisation of HK$31,764 million.
(THE Associated Press) Part3 Drug News Dual Mechanism Diabetes Therapy Two Phase 3 clinical trial results are positive Today, Lilly announced that its glucose-dependent insulin-promoting polypeptide and glucoglycline-like peptide-1-like peptide-1 complex agonist tirzepatide, in two Phase 3 clinical trials called SURFASS-3 and SURPASS-5 reached the primary and all critical secondary endpoints.
in a 52-week SURPASS-3 clinical trial, the highest dose of tirzepatide reduced glycation hemoglobin levels to normal levels in 48 percent of patients, while reducing the patient's weight by 12.9 kilograms.
(Pharmaceutical Minder) Treatment of Early Breast Cancer Olapali Phase 3 clinical trials ahead of the superiority standards February 18, AstraZeneca and Merca East jointly announced that the two companies jointly developed the PARP inhibitor Olapali, in the treatment of carrier BRCA mutation of high-risk HER2 negative early breast cancer Phase 3 clinical trials to obtain positive results.
based on a predetermined interim analysis, the Independent Data Monitoring Committee found that Olapali had reached the standard of superiority at the main endpoint compared to placebo and showed long-lasting, clinically relevant therapeutic effects.
(Drug Mingkangde) IL-15 super-excited to reach the clinical end of phase 2/3 today, ImmunityBio announced that its IL-15 super-excited complex Anktiva and card-based seedling, in the treatment of BCG poor response to non-myolytic immersive bladder cancer phase 2/3 clinical end.
71 percent of the 72 assessable patients treated with combination therapy achieved complete remission at a medium follow-up time of 10.7 months.
(Pharmaceutical Mingkangde) pioneering pharmaceutical GT90001 joint Nivolumab treatment of advanced liver cancer Phase II clinical trial application was approved on February 18, Pioneer Pharmaceuticals announced that its ALK-1 antibody GT90001 combined with Hundred Times Mercer's PD-1 single anti-Nivolumab second-line treatment of advanced liver cell carcinoma Phase II clinical trial application has been approved by the FDA.
GT90001 is an all-human IgG2-medium antibody that inhibits APK-1/TGF-β signal transducting and tumor angiogenesy.
(AAP) Baiji Shenzhou BTK inhibitor Zebtinib new adaptive disease listing application was accepted by the FDA on February 17, Baiji Shenzhou announced that the FDA has accepted Baiyue Zebtinib for the treatment of patients with Fahrenheit pythroidemia new adaptive disease listing application, PDUFA date is October 18, 2021.
Zebtini is a small molecular inhibitor of Bruton's tyrosine kinase developed by scientists in Baiji Shenzhou.
(Pharma Mission) NovartEntresto's treatment of HFpEE heart failure was approved by the FDA on Tuesday, Novarma Pharmaceuticals announced that the FDA has approved Enteresto's expanded use of blood fractions to retain heart failure patients.
with the approval of the extended label, Entresto became the first and only treatment to be approved for both types of heart failure.
Entresto is a bi-acting angiologistor-brain morphinease inhibitor that strengthens the heart's protective neuroendocrine system and is thought to reduce the strain on the failing heart.
(Sina Pharmaceutical News) Anjin KRAS inhibitor was approved by the FDA for priority review of treatment of non-small cell lung cancer on February 17, Amgen announced that the FDA has granted the company's KRAS G12C inhibitor sotorasib priority review qualification for the treatment of patients with local late stage or metastasis non-small cell lung cancer with KRAS G12C mutation, they have received at least one pre-systemic treatment.
the FDA is expected to respond by August 16.
(Pharmaceutical Mingkangde) Tiansli chlorovine flat tablets through generic drug consistency evaluation February 18, Tianslifa announced that the wholly-owned subsidiary Jiangsu Diyi received NMPA issued on the chlorine nitrogen tablets 25mg specifications of the "Drug Supplemental Application Approval Notice", the drug through generic drug consistency evaluation.
chlorine tablets are used to treat refractic schizophrenia, are essential national medicines, and are included in the National Health Insurance Directory (Category A).
(Tianshili Announcement) Junshi Bio: Ripley single anti-combination chemotherapy first-line treatment of nasopharyngeal cancer new adaptive disease listing application was accepted February 18, Junshi Bio announced that the company received NMPA approved the issuance of the "receiving notice", Ripley single-anti-combination chemotherapy for advanced first-line non-systematic treatment of relapsed metastatic nasopharyngeal cancer new adaptation application was accepted.
December 2020, Terripley's single-dose injection was successfully included in the new health-care list through the National Health Care Negotiations.
currently, Ripley monoantigen has been awarded 1 breakthrough therapy, 1 fast track and 3 orphan drug qualifications by the FDA in the fields of mucosal melanoma, nasopharyngeal cancer, and soft tissue sarcoma.
(Junshi Biological Announcement) Baiji Shenzhou introduced the new TNFR2 antagonist exclusive development rights On February 18, Baiji Shenzhou announced that it has reached a cooperative development agreement with BITT on the tumor necrotizing factor 2 antagonist antibody BITR2101, and obtained THE2101 exclusive development, production and commercialization options in Asia (except Japan), Australia and New Zealand.
under the terms of the agreement, BITT will receive an advance payment totalling $16.6 million and a recent milestone payment, including the exercise of the option by Baiji Shenzhou after the proof-of-concept study.
(Pharmaceutical Rubik's Cube) Green Leaf Pharmaceuticals granted exclusive rights to the Japanese market for the Mindo-Day skin-through patches of Toshi and Drug Liss today, Andersen Pharmaceuticals announced that its subsidiary has reached an agreement with Toshito Pharmaceuticals to grant the latter exclusive rights to the Development and Commercialization of the Japanese market for the Mindo-Day-to-Skin Paste.
's Mindo-Day permeable patch, which is used to treat Alzheimer's disease, is an innovative and innovative agent developed by Leafy Pharmaceuticals.
(Pharmaceutical Rubik's Cube) Howson introduced first in class oral antifungal drugs on February 17, Scynexis announced a strategic cooperation agreement with Howson Pharmaceuticals to grant the latter exclusive rights in the development and commercialization of ibrexafungerp in Greater China, including Hong Kong, Macau and Taiwan.
will make a $10 million down payment to Scynexis, as well as potential mileage and sales credits in the future.
Ibrexafungerp is a glucosin synthase inhibitor, a triamcinoid antifungal agent belonging to first in class, considered a new category of broad-spectrum oral/injected antifungal drugs.
(Pharmaceutical Rubik's Cube) East China Pharmaceuticals introduced dual-specific antibody PRV-3279 Greater China Development Rights on February 18, East China Pharmaceuticals announced that its wholly-owned subsidiary Hangzhou Sino-American East China Pharmaceutical Co., Ltd. signed a strategic cooperation agreement with The United States Development Bio Co., Ltd. to introduce Shuangte The heterosexual antibody PRV-3279 is the exclusive clinical development and commercialization interest in the treatment of systemic lupus erythematosus and immunogenicity in the prevention or reduction of gene therapy in Greater China (including Chinese mainland, Hong Kong, Macau and Taiwan).
(Pharmaceutical Rubik's Cube) developed an innovative antibody therapy for influenza GlaxoSmithKline and Vir Expanded Cooperation Today, GlaxoSmithKline and Vir Biotechnology announced that they have reached an agreement to expand existing research and development cooperation to develop innovative therapies for influenza and other respiratory viruses.
Under the agreement, GSK will receive exclusive research and development benefits for Vir's potential "best-in-class" monoclonal antibody therapy for influenza, including intramuscular injections called VIR-2482 in monoclonal antibodies for general preventive treatment of influenza A.
, which develops healing in vivo gene therapy, has between Novarma and the Gates Foundation, Novarma announced today that it has reached an agreement with the Bill and Melinda Gates Foundation.
as part of the agreement, the Gates Foundation will provide funding to develop a one-time in vivo gene therapy to cure sickle cell anemia (SCD).
SCD is an inherited blood disease that causes abnormal hemoglobin function due to a mutation in the gene that encodes the hemoglobin β peptide chain.
(Pharmaceutical Mingkang)